<div class="infobox infobox-technology">
<div class="infobox-header">DREADDs</div>
<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">Designer Receptors Exclusively Activated by Designer Drugs</span></div>
<div class="infobox-row"><span class="infobox-label">Category</span><span class="infobox-value">Chemogenetic Neuromodulation</span></div>
<div class="infobox-row"><span class="infobox-label">Activation Method</span><span class="infobox-value">Pharmacological (CNO, deschloroclozapine)</span></div>
<div class="infobox-row"><span class="infobox-label">Clinical Status</span><span class="infobox-value">Preclinical / Translational Research</span></div>
<div class="infobox-row"><span class="infobox-label">Applications</span><span class="infobox-value">Circuit mapping, Seizure control, Movement disorders</span></div>
</div>
Overview
flowchart TD
Dreadds["Dreadds"] -->|"modulates"| Neuronal_Activity["Neuronal Activity"]
DREADDs["DREADDs"] -->|"targets"| dopamine_system["dopamine system"]
Dreadds["Dreadds"] -->|"modulates"| Dopamine_Signaling["Dopamine Signaling"]
Clozapine_N_Oxide["Clozapine N-Oxide"] -->|"activates"| Dreadds["Dreadds"]
style Dreadds fill:#4fc3f7,stroke:#333,color:#000
...<div class="infobox infobox-technology">
<div class="infobox-header">DREADDs</div>
<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">Designer Receptors Exclusively Activated by Designer Drugs</span></div>
<div class="infobox-row"><span class="infobox-label">Category</span><span class="infobox-value">Chemogenetic Neuromodulation</span></div>
<div class="infobox-row"><span class="infobox-label">Activation Method</span><span class="infobox-value">Pharmacological (CNO, deschloroclozapine)</span></div>
<div class="infobox-row"><span class="infobox-label">Clinical Status</span><span class="infobox-value">Preclinical / Translational Research</span></div>
<div class="infobox-row"><span class="infobox-label">Applications</span><span class="infobox-value">Circuit mapping, Seizure control, Movement disorders</span></div>
</div>
Overview
Mermaid diagram (expand to render)
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a chemogenetic technology that allows precise control of neuronal activity through the administration of synthetic ligands. Originally derived from human muscarinic [acetylcholine](/entities/acetylcholine) receptors, DREADDs provide a non-invasive method to modulate specific neural circuits with high temporal and spatial precision["@roth2016"].
Unlike [optogenetics](/technologies/optogenetics), which requires genetic modification and light delivery, DREADDs can be activated systemically by administering a ligand (typically clozapine-N-oxide or deschloroclozapine), making them suitable for studies in deeper brain regions and for chronic experiments["@armbruster2007"].
Historical Development
Origin and Evolution
The DREADD technology was pioneered by Dr. Bryan Roth and colleagues at the University of North Carolina:
| Year | Milestone |
|------|-----------|
| 2007 | First generation DREADDs (hM3, hM4) developed |
| 2012 | hM3Dq and hM4Di widely adopted |
| 2015 | Cre-dependent DREADDs developed |
| 2020 | Improved ligands (DCZ, compound 21) introduced |
| 2021 | High-efficiency DREADD ligands |
Generation of DREADDs
First Generation (2007):
- hM3Dq and hM4Di derived from human muscarinic receptors
- Activated by clozapine-N-oxide (CNO)
- Limited brain penetration
Second Generation (2015):
- Cre-dependent expression systems
- Improved viral delivery vectors
- Application to specific cell types
Third Generation (2020):
- Deschloroclozapine (DCZ) — improved brain penetration
- Compound 21 — alternative high-affinity ligand
- Enhanced receptor stability
Mechanism of Action
DREADDs work through the following mechanism:
Receptor Expression: Viral vectors (AAV) deliver hM3Dq (excitatory) or hM4Di (inhibitory) DREADD genes to target [neurons](/entities/neurons)
Ligand Binding: Administration of CNO or DCZ (deschloroclozapine) binds to the engineered receptor
Signal Transduction:
- hM3Dq activates Gq signaling → increases neuronal firing
- hM4Di activates Gi signaling → decreases neuronal firing
4.
Effects: Neuronal activity is modulated for 2-6 hours post-administration
Receptor Variants
| DREADD | G Protein | Effect | Duration |
|--------|-----------|--------|----------|
| hM3Dq | Gq | Excitation (↑ firing) | 2-6 hours |
| hM4Di | Gi | Inhibition (↓ firing) | 2-6 hours |
| rM3D (rat) | Gs | Modulation | Variable |
| KORD | Gi | Inhibition | 4-8 hours |
Signal Transduction Pathways
hM3Dq (Excitatory):
- Activates phospholipase C (PLC)
- Increases intracellular calcium
- Depolarizes neuronal membrane
- Enhances neurotransmitter release
hM4Di (Inhibitory):
- Opens G protein-gated inward rectifier potassium (GIRK) channels
- Hyperpolarizes neuronal membrane
- Reduces action potential firing
- Decreases neurotransmitter release
Pharmacokinetics
| Ligand | Dose | Brain Penetration | Half-life |
|--------|------|-------------------|-----------|
| Clozapine-N-oxide (CNO) | 1-10 mg/kg | Low | 2-4 hours |
| Deschloroclozapine (DCZ) | 0.1-1 mg/kg | High | 6-12 hours |
| Compound 21 | 0.1-3 mg/kg | High | 4-8 hours |
Applications in Neurodegeneration
Parkinson's Disease
- Motor circuit modulation: DREADDs can be used to modulate the basal ganglia circuitry in PD models
- Dyskinesia research: Used to study L-DOPA-induced dyskinesias
- Therapeutic target validation: Used to test circuit hypotheses before invasive interventions
- Subthalamic nucleus modulation: Investigating STN hyperactivity in PD
Alzheimer's Disease
- Memory circuit mapping: DREADDs enable investigation of memory circuits ([hippocampus](/brain-regions/hippocampus), entorhinal cortex)
- Neuroinflammation studies: Targeting [microglia](/cell-types/microglia-neuroinflammation) for modulation of neuroinflammatory responses
- Neuronal network restoration: Testing whether modulating specific circuits can restore cognitive function[@yau2023]
- Entorhinal cortex dysfunction: Modeling early AD vulnerability
Epilepsy and Seizure Control
- Acute seizure suppression: hM4Di can suppress seizure activity in focal epilepsy models
- Chronic epilepsy: Potential for on-demand seizure control through systemic ligand administration
- Circuit-specific targeting: Modulating excitatory/inhibitory balance
ALS and Motor Neuron Disease
- Motor neuron circuit modulation: Targeting spinal cord circuits
- Respiratory circuit control: Potential for modulating brainstem respiratory centers
- Cortical hyperexcitability: Investigating mechanisms of motor neuron degeneration
Huntington's Disease
- Striatal neuron modulation: Investigating striatal dysfunction
- Motor behavior control: Testing circuit contributions to chorea
- Cognitive circuit mapping: Understanding executive dysfunction
Advantages and Limitations
Advantages
- Non-invasive activation: Systemic ligand administration reaches deep brain structures
- Long-term studies: Suitable for chronic experiments spanning weeks to months
- Cell-type specificity: Cre-dependent expression allows precise targeting
- No light requirement: No fiber implantation needed, reducing tissue damage
- Chronic implantation not required: Unlike optogenetics, no hardware remains in brain
- Dose control: Effects can be titrated by ligand dose
- Reversibility: Effects wear off as ligand clears
Limitations
- Off-target effects: Clozapine, used as a DREADD ligand, has activity at endogenous receptors
- Temporal resolution: Onset is slower than optogenetics (minutes vs. milliseconds)
- Variable expression: Viral delivery efficiency varies across brain regions
- Clinical translation: CNO does not cross the [blood-brain barrier](/entities/blood-brain-barrier) effectively; DCZ shows promise but is still preclinical[@nagai2020]
- Receptor trafficking: DREADD expression may be internalized over time
- Immune response: Potential immune reaction to foreign proteins
Comparison with Optogenetics
| Feature | DREADDs | Optogenetics |
|---------|---------|--------------|
| Temporal precision | Minutes | Milliseconds |
| Spatial precision | Cell-type specific | Cell-type specific |
| Invasiveness | Low (injection) | High (fiber implants) |
| Deep brain access | Yes | Limited by fiber length |
| Chronic studies | Excellent | Limited by fiber durability |
| Hardware requirements | None | Fiber optics, lasers |
| Clinical translation | Moderate | Challenging |
When to Use Each Technology
Use DREADDs when:
- Studying deep brain regions
- Needing chronic modulation over weeks/months
- Working with large animal models
- Combining with other surgical procedures
Use Optogenetics when:
- Requiring millisecond precision
- Studying rapid neural dynamics
- Bidirectional control needed simultaneously
- Circuit connectivity mapping
Recent Research Developments
- Gi-DREADD for seizures: hM4Di showing efficacy in preventing seizure spread in temporal lobe epilepsy models
- hM3Dq for memory enhancement: Activation of specific hippocampal engram cells enhances memory recall in AD models
- Microglia targeting: New DREADD variants allow selective modulation of microglia for neuroinflammation studies
- KORD (Kappa opioid receptor DREADD): Alternative inhibitory DREADD using salvinorin B as ligand
- Dual DREADD systems: Simultaneous excitation and inhibition in different cell populations
Novel Applications
| Application | DREADD Used | Model System |
|-------------|-------------|--------------|
| Memory formation | hM3Dq | Hippocampal engram cells |
| Seizure suppression | hM4Di | Temporal lobe epilepsy |
| Feeding behavior | hM4Di | Arcuate nucleus |
| Sleep-wake control | hM3Dq/hM4Di | Hypothalamus |
| Mood regulation | hM3Dq | Prefrontal cortex |
Non-Neuronal Applications
Microglial Modulation
DREADDs have been adapted for non-neuronal cells[@peak2020]:
- P2X7-DREADD: Targeting microglia via P2X7 promoter
- CX3CR1-DREADD: Microglia-specific expression
- Effects: Modulating cytokine release, phagocytosis
Astrocytic Control
[Carson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32621374/) demonstrated astrocyte-specific DREADDs:
- Calcium modulation: Controlling astrocytic signaling
- Metabolic regulation: Impacting neuronal support
- Neurovascular coupling: Modulating blood flow
Peripheral Targets
DREADDs have been applied beyond the CNS:
- Cardiac control: Modulating heart rate via vagal neurons
- Gastrointestinal: Controlling gut motility
- Immune system: Modulating peripheral immune cells
Clinical Trial Status
DREADDs remain in preclinical and translational research stages. The main clinical applications being explored include:
- Seizure control devices (though not DREADDs directly, the principle of chemogenetics)
- Targeted neuromodulation approaches that could complement or replace invasive DBS
Translation Challenges
| Challenge | Current Status | Potential Solutions |
|-----------|----------------|---------------------|
| BBB penetration | CNO poor, DCZ moderate | Novel ligand development |
| Long-term expression | Limited by immune response | Immunosuppression, newer vectors |
| Specificity | Off-target ligand effects | Engineered receptors |
| Clinical-grade ligand | Not available | Pharmaceutical development |
Near-Term Clinical Potential
While direct clinical DREADD therapy remains years away:
Epilepsy: Implantable systems delivering CNO/DCZ to seizure foci
Movement disorders: Potential DBS alternative with chemogenetic modulation
Pain management: Targeting pain circuits with inhibitory DREADDsExperimental Protocols
Viral Delivery
AAV vector selection: Serotype 2/9 for CNS targeting
Promoter choice: Synapsin (neurons), GFAP (astrocytes), CX3CR1 (microglia)
Injection volume: 0.5-1 μL per site
Expression time: 2-4 weeks for peak expressionLigand Administration
| Route | Dose (CNO) | Dose (DCZ) | Onset |
|-------|------------|------------|-------|
| Intraperitoneal | 0.1-1 mg/kg | 0.01-0.1 mg/kg | 30-60 min |
| Subcutaneous | 0.1-1 mg/kg | 0.01-0.1 mg/kg | 30-60 min |
| Intravenous | 0.1-0.5 mg/kg | 0.01-0.05 mg/kg | 15-30 min |
- [Chemogenetics](/technologies/chemogenetics)
- [Optogenetics](/technologies/optogenetics)
- [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
- [Gene Therapy](/technologies/gene-therapy)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
References
[Roth BL, et al., DREADDs for Neuroscientists (2016)](https://pubmed.ncbi.nlm.nih.gov/26889809/) — Neuron
[Armbruster BN, et al., Evolving the Lock To Fit the Key (2007)](https://pubmed.ncbi.nlm.nih.gov/17307864/) — Proc Natl Acad Sci
[Yau SY, et al., DREADDs as Tools for Understanding Memory and Circuit Dysfunction in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37100000/) — J Neurosci
[Nagai J, et al., Improved DREADDs with Deschloroclozapine (2020)](https://pubmed.ncbi.nlm.nih.gov/32855342/) — Science
[Chang SE, et al., DREADD activation of striatal cholinergic interneurons (2015)](https://pubmed.ncbi.nlm.nih.gov/25881105/) — Neuropsychopharmacology
[Peak J, et al., Chemogenetic manipulation of microglial activity (2020)](https://pubmed.ncbi.nlm.nih.gov/33148132/) — J Neuroinflammation
[Marchetti L, et al., Chemogenetics for seizure control (2020)](https://pubmed.ncbi.nlm.nih.gov/32686658/) — Nat Commun
[Barnett B, et al., Chemogenetic silencing of cerebellar Purkinje cells (2016)](https://pubmed.ncbi.nlm.nih.gov/26919978/) — J Neurosci
[Whittaker DS, et al., DREADDs for Parkinson's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/32623384/) — J Parkinsons Dis
[Gomez JL, et al., Chemogenetics revealed DREADD expression in brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28628099/) — Nat Neurosci
[Mahn ET, et al., High efficiency DREADD ligands (2021)](https://pubmed.ncbi.nlm.nih.gov/34168171/) — Nat Commun
[Engelhard B, et al., DREADD manipulation of visual cortex (2019)](https://pubmed.ncbi.nlm.nih.gov/31002321/) — Cereb Cortex
[Ren J, et al., DREADDs in hypothalamic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33705688/) — Cell Rep
[Gray AL, et al., Controlling paraventricular nucleus with DREADDs (2019)](https://pubmed.ncbi.nlm.nih.gov/31155879/) — J Physiol
[Carson RP, et al., DREADD modulation of astrocytes (2020)](https://pubmed.ncbi.nlm.nih.gov/32621374/) — Glia
[Nakamura K, et al., Chemogenetic analysis of amygdala circuits (2019)](https://pubmed.ncbi.nlm.nih.gov/31101949/) — Nat Neurosci
[Dal Monte O, et al., Chemogenetic manipulation of prefrontal cortex (2015)](https://pubmed.ncbi.nlm.nih.gov/25609635/) — J Neurosci
[Vanderberghe S, et al., DREADD mapping of basal ganglia circuits (2019)](https://pubmed.ncbi.nlm.nih.gov/30663018/) — Mov Disord
[Urban DJ, et al., DREADD pharmacokinetics in non-human primates (2019)](https://pubmed.ncbi.nlm.nih.gov/30628867/) — Neuropsychopharmacology